A phase Ib study investigating the combination of everolimus and dovitinib in vascular endothelial growth factor refractory clear cell renal cancer. [electronic resource]
Producer: 20140826Description: 2057-64 p. digitalISSN:- 1879-0852
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Benzimidazoles -- administration & dosage
- Carcinoma, Renal Cell -- drug therapy
- Cohort Studies
- Disease-Free Survival
- Dose-Response Relationship, Drug
- Everolimus
- Fatigue -- chemically induced
- Female
- Humans
- Kaplan-Meier Estimate
- Kidney Neoplasms -- drug therapy
- Male
- Middle Aged
- Quinolones -- administration & dosage
- Sirolimus -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.